

Milltrust Ventures to invest in first-in-class health tech platform Oncoshot

22 March 2022 | News

Oncoshot is a health insights exchange platform that leverages its proprietary clinical trial matching artificial intelligence (AI) technology to address the inefficiencies of cancer clinical trials



Oncoshot has announced it will be welcoming Dr Bernard Ng, Chief Scientific Officer of Milltrust Ventures, to its advisory board this month. This comes as a first step as the specialist investment organization finances the fast-growing health tech company founded in Singapore.

Milltrust Ventures is a subsidiary of Milltrust International Group, a specialist investment organization co-headquartered in the asset management hubs of London and Singapore. It invests in early-stage high-potential companies with a focus on science and technology that can positively impact individual health and healthcare systems. Milltrust Ventures screens and identifies start-ups from the British and European ecosystems, and Asia, particularly Singapore, home to a thriving start-up ecosystem with strong backing and support from good policies and government assistance.

Oncoshot is a health insights exchange platform that leverages its proprietary clinical trial matching artificial intelligence (AI) technology to address the inefficiencies of cancer clinical trials. The platform serves as a bridge between leading regional healthcare institutions and contract research organizations (CROs) and global biotechnology and pharmaceutical companies to facilitate data-driven cancer clinical trials while accelerating enrolment into actively recruiting ones.